Integrated analysis identifies oxidative stress-related lncRNAs associated with progression and prognosis in colorectal cancer

Abstract

Background Colorectal cancer (CRC) is one of the most common cancers in the world. Oxidative stress reactions have been reportedly associated with oncogenesis and tumor progression. By analyzing mRNA expression data and clinical information from The Cancer Genome Atlas (TCGA), we aimed to construct an oxidative stress-related long noncoding RNA (lncRNA) risk model and identify oxidative stress-related biomarkers to improve the prognosis and treatment of CRC. Results Differentially expressed oxidative stress-related genes (DEOSGs) and oxidative stress-related lncRNAs were identified by using bioinformatics tools. An oxidative stress-related lncRNA risk model was constructed based on 9 lncRNAs (AC034213.1, AC008124.1, LINC01836, USP30-AS1, AP003555.1, AC083906.3, AC008494.3, AC009549.1, and AP006621.3) by least absolute shrinkage and selection operator (LASSO) analysis. The patients were then divided into high- and low-risk groups based on the median risk score. The high-risk group had a significantly worse overall survival (OS) (p < 0.001). Receiver operating characteristic (ROC) and calibration curves displayed the favorable predictive performance of the risk model. The nomogram successfully quantified the contribution of each metric to survival, and the concordance index and calibration plots demonstrated its excellent predictive capacity. Notably, different risk subgroups showed significant differences in terms of their metabolic activity, mutation landscape, immune microenvironment and drug sensitivity. Specifically, differences in the immune microenvironment implied that CRC patients in certain subgroups might be more responsive to immune checkpoint inhibitors. Conclusions Oxidative stress-related lncRNAs can predict the prognosis of CRC patients, which provides new insight for future immunotherapies based on potential oxidative stress targets.

A novel disulfidptosis-related lncRNA signature in colorectal cancer for predicting prognosis, tumor immune microenvironment features and drug sensitivity

“…SUCLG2-AS1 was found to be abnormally expressed in acute myeloid leukemia and a variety of tumors, affecting the development of nasopharyngeal carcinoma, triple-negative breast cancer, clear cell renal cell carcinoma and gastric cancer [20][21][22][23] . Moreover, AP003555.1 was identi ed and validated as a novel ferroptosis-related and oxidative stressrelated lncRNA and incorporated into a prognostic model for colon cancer [24][25] . However, the roles and functions of AC011815.1, AC109992.2, AC069549.1 and AL590101.1 have not been previously reported.…”

Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer

“…In particular, AP003555.1 was reported to be an effective prognostic element in signatures based on ferroptosis-related lncRNAs, which also indirectly suggests the strong relationship between ferroptosis and disulfidptosis [ 14 , 15 ]. ATP2B1.AS1 is strongly associated with cell inflammation and can regulate the miR-23a-3p/TLR4 axis, exacerbating sepsis-induced cell apoptosis and inflammation [ 17 ]. Furthermore, it has been found to promote cerebral ischemia/reperfusion injury and worsen myocardial infarction by activating the NF-κB signaling pathway [ 18 , 19 ].…”

Disulfidptosis-related lncRNAs are potential biomarkers for predicting prognoses in patients with hepatocellular carcinoma

“…Next, we developed a nomogram that could better anticipate HCC patients' OS at 1, 3, and 5 years. The AC009549.1, AL136419.3 has been reported to associated with progression and prognosis in colorectal cancer, head and neck squamous cell carcinoma, [29,30] . The AL928654.1, MKLN1-AS, TMCC1-AS1 were found as lncRNAs related to the progression of HCC [31][32][33] , while AC138696.2, AL449106.1 have not been studied yet.…”